Clinical TrialMay 7, 2026, 07:42 AM
Cardiol Therapeutics Phase II MAvERIC Results Accepted for Publication
AI Summary
Cardiol Therapeutics announced that the results from its Phase II MAvERIC study, evaluating CardiolRx in patients with recurrent pericarditis, have been accepted for publication in the Journal of the American Heart Association (JAHA). The study demonstrated that CardiolRx was associated with rapid and sustained reductions in pericarditis pain and inflammation, along with a substantial reduction in pericarditis episodes per year and a favorable safety profile. These findings provide important clinical validation for the ongoing pivotal Phase III MAVERIC trial, which has now surpassed 75% enrollment.
Key Highlights
- Cardiol Therapeutics' Phase II MAvERIC results accepted for publication in the Journal of the American Heart Association (JAHA).
- CardiolRx was associated with rapid and sustained reductions in pericarditis pain and inflammation.
- The study reported a substantial reduction in pericarditis episodes per year.
- CardiolRx demonstrated a favorable safety and tolerability profile.
- The results provide clinical rationale for the ongoing pivotal Phase III MAVERIC trial, which recently surpassed 75% enrollment.
- CardiolRx has Orphan Drug Designation from the U.S. FDA for pericarditis.